List view / Grid view
22 February 2017 | By Niamh Marriott, Digital Editor
Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of…
21 February 2017 | By Niamh Marriott, Digital Editor
Researchers at MIT have found a new way of using mid-infrared lasers to turn regions of molecules into glowing filaments of electrically charged gas...
21 February 2017 | By Niamh Marriott, Digital Editor
VTT Technical Research Centre of Finland has developed a miniature gas sensor that can be connected to mobile devices.
21 February 2017 | By Niamh Marriott, Digital Editor
A new study has tied the World Trade Centre (WTC) site with paresthesias, a nerve-related issue causing burning or prickling sensations...
20 February 2017 | By Johanna Laiho-Kauranne, Director of Statistics, Luke
Johanna Laiho-Kauranne examines the 17 UN sustainable development goals that have been implemented for monitoring sustainability development...
20 February 2017 | By Niamh Marriott, Digital Editor
Umeå University researches have established links between patterns of malaria in Kenya and environmental factors measurable by satellite imagery...
20 February 2017 | By Niamh Marriott, Digital Editor
Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.
17 February 2017 | By Niamh Marriott, Digital Editor
Custom Pharma Services, the Brighton based CDMO, is pleased to announce the commencement of the building work on its £20 million Pharmaceutical Innovation Centre (PIC) in Moulsecoomb, Brighton. The Custom PIC will house the contract development, clinical and commercial manufacturing teams in a new, purpose built facility. This investment is…
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon's biologics license application for MYL-1401H, a proposed biosimilar to Neulasta...
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or…
16 February 2017 | By WITec
WITec presents a new operating concept with the powerful and intuitive Suite FIVE at Pittcon 2017...
16 February 2017 | By Niamh Marriott, Digital Editor
The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
16 February 2017 | By Niamh Marriott, Digital Editor
Sophia Genetics announced that ten new genomic institutions from Latin America have started using SOPHiA to democratise access to clinical genomics...
13 February 2017 | By Niamh Marriott, Digital Editor
NICE published draft guidance recommending ponatinib (Iclusig, Incyte Corporation) for routine use on the NHS, to treat chronic myeloid leukaemia...
